bioRxiv · 10.1101/2020.07.22.215426
A novel PS4 criterion approach based on symptoms of rare diseases and in-house frequency data in a Bayesian framework.
Abstract
The American College of Medical Genetics (ACMG) and Genomics/Association for Molecular Pathology (AMP) previously reported standardized guidance for the assessment of genetic variants. One of the criteria regarding the prevalence in a case-control study, PS4, is important due to its evidence of pathogenicity. Despite recent studies approaching gene- and disease-specific probands, interpretation of a variant to PS4 still has certain limitations for rare variants. Here, we suggest a generalized method, Bayesian odds ratio (BayesianOR), applicable to PS4 via decomposing a disease to its symptoms and applying a Bayesian framework. Using this approach, we demonstrate reproducibility of the calculation of the original odds ratio from well-studied epilepsy data and verify the applicability to in-house frequencies for various rare diseases. In addition, BayesianOR showed a significant difference in tendency with different ClinVar pathogenicity, using in-house data. Thus, the novel method described here should provide an improved interpretation of sequence variants. Furthermore, we anticipate that it will enhance the diagnosis of patients with rare diseases.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Cho, Y. K., Won, D.-g., Keum, C., Seo, G. H., Lee, B. H., Lee, B.-C.. 2020-07-24. A novel PS4 criterion approach based on symptoms of rare diseases and in-house frequency data in a Bayesian framework.. https://doi.org/10.1101/2020.07.22.215426
Cite the original work for its findings. Save a collection to share your selection of sources.